Entropy Technologies LP Sells 1,634 Shares of Cencora, Inc. (NYSE:COR)

Entropy Technologies LP lessened its stake in Cencora, Inc. (NYSE:COR - Free Report) by 17.8% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,560 shares of the company's stock after selling 1,634 shares during the quarter. Entropy Technologies LP's holdings in Cencora were worth $1,699,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Lake Street Advisors Group LLC increased its position in shares of Cencora by 1.3% during the third quarter. Lake Street Advisors Group LLC now owns 3,415 shares of the company's stock valued at $769,000 after acquiring an additional 43 shares during the last quarter. Venturi Wealth Management LLC increased its position in shares of Cencora by 1.0% during the third quarter. Venturi Wealth Management LLC now owns 4,447 shares of the company's stock valued at $1,001,000 after acquiring an additional 46 shares during the last quarter. Prime Capital Investment Advisors LLC increased its position in shares of Cencora by 1.2% during the third quarter. Prime Capital Investment Advisors LLC now owns 3,768 shares of the company's stock valued at $848,000 after acquiring an additional 46 shares during the last quarter. Shepherd Financial Partners LLC increased its position in shares of Cencora by 0.9% during the fourth quarter. Shepherd Financial Partners LLC now owns 5,441 shares of the company's stock valued at $1,223,000 after acquiring an additional 46 shares during the last quarter. Finally, J.W. Cole Advisors Inc. increased its position in shares of Cencora by 1.3% during the third quarter. J.W. Cole Advisors Inc. now owns 3,669 shares of the company's stock valued at $826,000 after acquiring an additional 48 shares during the last quarter. Institutional investors own 97.52% of the company's stock.

Cencora Stock Performance

Shares of NYSE COR traded up $1.05 during mid-day trading on Thursday, hitting $244.64. The company had a trading volume of 1,819,104 shares, compared to its average volume of 1,525,452. The company has a market capitalization of $47.28 billion, a price-to-earnings ratio of 34.80, a P/E/G ratio of 1.49 and a beta of 0.49. Cencora, Inc. has a 1 year low of $214.77 and a 1 year high of $262.26. The stock's 50-day moving average price is $238.70 and its 200-day moving average price is $237.21. The company has a current ratio of 0.92, a quick ratio of 0.53 and a debt-to-equity ratio of 16.40.

Cencora (NYSE:COR - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $3.73 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.50 by $0.23. Cencora had a return on equity of 328.62% and a net margin of 0.46%. On average, sell-side analysts forecast that Cencora, Inc. will post 15.36 earnings per share for the current year.

Cencora Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 3rd. Investors of record on Friday, February 14th will be paid a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a yield of 0.90%. The ex-dividend date of this dividend is Friday, February 14th. Cencora's dividend payout ratio is 31.29%.

Insider Activity at Cencora

In other Cencora news, EVP Silvana Battaglia sold 1,678 shares of Cencora stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $228.72, for a total transaction of $383,792.16. Following the completion of the sale, the executive vice president now owns 20,329 shares of the company's stock, valued at $4,649,648.88. The trade was a 7.62 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Chairman Steven H. Collis sold 50,000 shares of Cencora stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $243.97, for a total value of $12,198,500.00. Following the sale, the chairman now directly owns 326,557 shares of the company's stock, valued at approximately $79,670,111.29. This trade represents a 13.28 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 73,187 shares of company stock valued at $17,790,912. Company insiders own 10.80% of the company's stock.

Wall Street Analysts Forecast Growth

A number of analysts recently commented on COR shares. Mizuho started coverage on Cencora in a research report on Wednesday, December 4th. They set an "outperform" rating and a $280.00 price target for the company. JPMorgan Chase & Co. increased their price target on Cencora from $289.00 to $301.00 and gave the company an "overweight" rating in a research report on Friday, January 24th. Barclays raised their target price on Cencora from $263.00 to $290.00 and gave the stock an "overweight" rating in a research report on Thursday, November 7th. Wells Fargo & Company raised their target price on Cencora from $237.00 to $251.00 and gave the stock an "equal weight" rating in a research report on Wednesday, January 29th. Finally, Evercore ISI raised their target price on Cencora from $270.00 to $280.00 and gave the stock an "outperform" rating in a research report on Thursday, February 6th. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $277.90.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.